We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Antigen Test Evaluated for Blastomycosis

By LabMedica International staff writers
Posted on 15 Feb 2011
Print article
A commercially available assay for detection of Blastomyces dermatitidis antigen has been modified to permit quantitation in subjects with newly diagnosed blastomycosis.

An sandwich enzyme immunoassay (EIA) is available that will detect the antigen of the pathogenic mycoses B. dermatitidis in patients' serum, urine, cerebral spinal fluid, and other sterile body fluids.

In a study carried out at the University of Arkansas for Medical Sciences (Little Rock, AR, USA), samples were assayed from patients with newly diagnosed blastomycosis. Specimens from 27 subjects were analyzed and urine specimens from 25 healthy subjects and 25 subjects with conditions other than histoplasmosis or blastomycosis were analyzed to provide negative controls. If no antigen was detectable, the urine specimen was concentrated 10-fold and reanalyzed. Serum specimens were tested before and after treatment with ethylenediaminetetraacetic acid (EDTA) to dissociate immune complexes. Treatment of specimens with EDTA has not been shown to cause false-positive results in another fungal assay.

The assay used was the Mvista Blastomyces dermatitidis Antigen EIA, (MiraVista Diagnostics, Indianapolis, IN, USA). Of 27 patients, 23 (85.1%) had detectable B. dermatitidis antigen detected in their urine samples with a median of a 1.49 ng/mL, with a range of 0.21 ng/mL - 16.90 ng/mL. In two of these 23, positive results were obtained only after concentration of the urine specimen. Nine of 11 (81.8%) subjects had detectable B. dermatitidis antigen in their serum, including three subjects with negative results before treatment of serum with EDTA and positive results after EDTA treatment. B. dermatitidis antigen was not detected in specimens from 50 control subjects, but was detected in 15 patients with histoplasmosis. The authors concluded that the B. dermatitidis antigen was detected in most of the patients with blastomycosis and that it can be a useful tool for timely diagnosis. The study was published in February 2011, in the journal Diagnostic Microbiology and Infectious Disease.

Blastomycosis is an infection caused by inhaling microscopic spores produced by the fungus B. dermatitidis. Blastomycosis may be limited to the lungs or also involve the skin and bones. In its most severe form, the infection can spread throughout the body and become systemic. The fungus that causes the disease is found in moist soil and wood in the southeastern US, the Mississippi River valley, southern Canada, and Central America.

Related Links:

University of Arkansas for Medical Sciences
MiraVista Diagnostics



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Vaginitis Test
Allplex Vaginitis Screening Assay
New
Auto Clinical Chemistry Analyzer
cobas c 703

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.